6/29/23, 1:09 AM RECOVERY (lopinavir-ritonavir) Pathway Feedback Search Clinical Topics Home Studies RECOVERY (lopinavir-ritonavir) RECOVERY (lopinavir-ritonavir) Disease COVID 19 infection Trial question What is the role of lopinavir-ritonavir in patients admitted to hospital with COVID-19? Study design Multi-center Open label RCT Population Characteristics of study participants 39.0% female N = 5040 61.0% male 5040 patients (1963 female, 3077 male) Inclusion criteria: patients admitted to hospital with COVID-19 Key exclusion criteria: severe hepatic insufficiency, using medicinal products that are highly dependent on cytochrome P450 3A4 for clearance and for whom elevated plasma concentrations would be associated with serious or life-threatening events Interventions N=1616 lopinavir-ritonavir (400 mg and 100 mg by mouth every 12 h for 10 days or until discharge) N=3424 usual care (standard of care) Primary outcome https://web.pathway.md/studies/recNgo5eyBTbG2PgA 1/2 6/29/23, 1:09 AM RECOVERY (lopinavir-ritonavir) Pathway Death from all causes at 28 days 23.0 % 23 22 17.3 % 11.5 % 5.8 % No significant difference 0.0 % Lopinavir-ritonavir Usual care No significant difference in death from all causes at 28 days (23% vs. 22%; RR 1.03, 95% CI 0.91 to 1.17) Secondary outcomes No significant difference in the rate of discharge from hospital within 28 days (69% vs. 70%; RR 0.98, 95% CI 0.91 to 1.05) No significant difference in receipt of invasive mechanical ventilation or death (29% vs. 27%; RR 1.09, 95% CI 0.99 to 1.2) No significant difference in invasive mechanical ventilation (10% vs. 9%; RR 1.15, 95% CI 0.95 to 1.39) Safety outcomes No significant difference in cardiac arrhythmias and requirement of renal dialysis or hemofiltration. Conclusion In patients admitted to hospital with COVID-19, lopinavir-ritonavir was not superior to usual care with respect to death from all causes at 28 days. Reference Peter W Horby, Marion Mafham, Jennifer L Bell et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020 Oct 5;396(10259):1345-1352. Open reference URL https://web.pathway.md/studies/recNgo5eyBTbG2PgA 2/2